Thomson Horstmann & Bryant Inc. Increases Position in LeMaitre Vascular, Inc. (LMAT)

Thomson Horstmann & Bryant Inc. increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 365,977 shares of the medical instruments supplier’s stock after buying an additional 6,638 shares during the period. LeMaitre Vascular makes up approximately 1.5% of Thomson Horstmann & Bryant Inc.’s investment portfolio, making the stock its 16th largest position. Thomson Horstmann & Bryant Inc.’s holdings in LeMaitre Vascular were worth $11,425,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. American International Group Inc. raised its position in LeMaitre Vascular by 7.0% in the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 545 shares in the last quarter. Capstone Asset Management Co. acquired a new stake in LeMaitre Vascular during the second quarter valued at approximately $243,000. Bank of Montreal Can increased its stake in LeMaitre Vascular by 32.2% in the first quarter. Bank of Montreal Can now owns 10,483 shares of the medical instruments supplier’s stock valued at $258,000 after buying an additional 2,552 shares in the last quarter. Blair William & Co. IL increased its stake in LeMaitre Vascular by 6.9% in the first quarter. Blair William & Co. IL now owns 11,977 shares of the medical instruments supplier’s stock valued at $295,000 after buying an additional 768 shares in the last quarter. Finally, Eqis Capital Management Inc. acquired a new stake in LeMaitre Vascular during the second quarter valued at approximately $311,000. Hedge funds and other institutional investors own 66.45% of the company’s stock.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) traded up 0.07% during mid-day trading on Monday, hitting $28.33. 21,798 shares of the company traded hands. The stock has a market capitalization of $532.86 million, a price-to-earnings ratio of 47.30 and a beta of 0.63. LeMaitre Vascular, Inc. has a one year low of $14.04 and a one year high of $33.22. The company’s 50-day moving average is $29.84 and its 200-day moving average is $26.54.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.03. LeMaitre Vascular had a net margin of 12.52% and a return on equity of 13.36%. The firm had revenue of $24.10 million during the quarter, compared to analysts’ expectations of $23.48 million. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts predict that LeMaitre Vascular, Inc. will post $0.70 EPS for the current year.

LMAT has been the subject of several recent research reports. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Friday, April 28th. Stifel Nicolaus boosted their target price on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Canaccord Genuity reissued a “buy” rating and issued a $28.00 target price on shares of LeMaitre Vascular in a research report on Thursday, April 27th. Benchmark Co. downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. Finally, Craig Hallum initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 target price for the company. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $27.00.

In other news, Chairman George W. Lemaitre sold 87,342 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $32.35, for a total value of $2,825,513.70. Following the completion of the sale, the chairman now owns 3,484,149 shares of the company’s stock, valued at $112,712,220.15. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Michael T. Wijas sold 2,346 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $31.42, for a total transaction of $73,711.32. Following the completion of the sale, the vice president now directly owns 3,584 shares of the company’s stock, valued at approximately $112,609.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 317,805 shares of company stock valued at $9,910,332. Company insiders own 23.70% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).